AMERISAFE, Inc. Q2 2026 Earnings Call Summary
AMERISAFE reported Q2 2026 net premiums earned up 11.4% year over year for the ninth straight quarter, with renewal retention above 93% and a 72% current accident year loss ratio. The company recorded $7.3M favorable prior-year reserve development and a 31.8% expense ratio after a $700k bad debt write-off. Net investment income fell 2.4% and it repurchased shares at $30.58.
How this was made
The 30-second read
Why it matters
The call suggests continued profitable growth supported by retention and disciplined pricing, while highlighting ongoing medical inflation and expense/investment headwinds that could affect margins and forward sentiment.
Market read
New, company-specific operating metrics and outlook framing can drive positioning around workers’ compensation insurers’ loss-cost and medical inflation sensitivity.
What to watch
The expense ratio increase is tied to a single large account write-off, and the investment income decline reflects capital returns; traders may want to separate one-off credit effects from sustainable earnings power.
Background
The piece summarizes AMERISAFE’s Q2 2026 earnings call, focusing on underwriting performance, loss ratios, reserve development, investment income, and 2027 rate filing expectations.
Ticker impact
AMERISAFE reported Q2 2026 results and guidance, including 11.4% net premium growth, 72% accident-year loss ratio, and a $700k bad-debt write-off.
Near-term sentiment likely mixed, with support from growth and reserve development offset by expense and medical inflation concerns.
The article provides multiple concrete operating metrics (growth, retention, loss ratio, prior-year reserve development) plus specific headwinds (bad debt write-off, medical inflation, net investment income decline). However, it lacks consensus estimates or explicit forward guidance numbers beyond a mid-single-digit growth trajectory.
Market effects
Workers’ comp insurers may face similar medical inflation and rate-decrease dynamics; AMERISAFE’s commentary highlights how pricing discipline and fee schedules can mitigate severity pressure.
California rate-increase discussion is framed as industry-wide recognition of medical inflation, even though AMERISAFE does not operate there.
Limited direct global impact; the story is primarily US workers’ compensation underwriting and medical cost inflation.
Counterpoint
The favorable prior-year reserve development and slightly lower six-month severity may not persist, so the apparent underwriting strength could be partly timing-driven.
Key entities
- companyAMERISAFE, Inc.
Subject of the earnings call summary, reporting Q2 2026 underwriting metrics, expense ratio drivers, investment income changes, and outlook.
